Uncommon Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $13.2M

  • Investors
  • 21

Uncommon General Information

Description

Developer of an RNA-delivery and multi-pathway therapeutic system intended to support combination-based RNA treatments. The company's platform uses a polysaccharide-based delivery system capable of carrying multiple RNA types simultaneously, supports stability for extended periods, operates without PEG, enables multi-target modulation, incorporates an engine for programmable RNA combinations, and provides scalable performance across disease pathways, enabling biotechnology and therapeutic developers to address complex, multi-mechanism conditions more effectively.

Contact Information

Website
www.symphorna.com
Formerly Known As
HigherSteaks
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Bio-Innovation Centre 25
  • Cambridge Science Park Road, Milton
  • Cambridge CB4 0FW
  • England, United Kingdom
Primary Industry
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Bio-Innovation Centre 25
  • Cambridge Science Park Road, Milton
  • Cambridge CB4 0FW
  • England, United Kingdom

Uncommon Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Uncommon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 25-Nov-2024 $13.2M Completed Generating Revenue
8. Later Stage VC (Series A) 06-Apr-2023 Completed Generating Revenue
7. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
6. Early Stage VC 04-May-2021 Completed Generating Revenue
5. Seed Round 01-Jan-2020 Completed Generating Revenue
4. Accelerator/Incubator 05-Feb-2019 Completed Generating Revenue
3. Seed Round 22-Oct-2018 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Uncommon’s complete valuation and funding history, request access »

Uncommon Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A2
Series A
Seed
Seed
Seed 108,625 $0.012807 $2.22 $2.22 1x $2.22 2.28%
Seed 440,600 $0.012807 $2.77 $2.77 1x $2.77 9.27%
To view Uncommon’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Uncommon Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an RNA-delivery and multi-pathway therapeutic system intended to support combination-based RNA treatments.
Biotechnology
Cambridge, United Kingdom
11 As of 2026

Yokneam Ilit, Israel
 

Maastricht, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Uncommon Competitors (3)

One of Uncommon’s 3 competitors is ProFuse Technology, a Venture Capital-Backed company based in Yokneam Ilit, Israel.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ProFuse Technology Venture Capital-Backed Yokneam Ilit, Israel
Mosa Meat Venture Capital-Backed Maastricht, Netherlands
Aleph Farms Venture Capital-Backed Rehovot, Israel
You’re viewing 3 of 3 competitors. Get the full list »

Uncommon Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 5

    Pending

  • Expiring in next 12 mo

Uncommon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4562126-A1 Methods and compositions for cell culturing Pending 28-Jul-2022
US-20250243466-A1 Methods and compositions for cell culturing Pending 28-Jul-2022
AU-2022395910-A1 Methods and compositions for protein expression and cell differentiation Pending 23-Nov-2021
EP-4437118-A2 Methods and compositions for protein expression and cell differentiation Pending 23-Nov-2021
US-20240360441-A1 Methods and compositions for protein expression and cell differentiation Pending 23-Nov-2021 C12N15/11
To view Uncommon’s complete patent history, request access »

Uncommon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Uncommon Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
Global Brain Venture Capital Minority
Heartfelt (Private Equity) Venture Capital Minority
Angel Academe Angel Group Minority
Balderton Capital Venture Capital Minority
BioIndustry Association Accelerator/Incubator Minority
You’re viewing 5 of 21 investors. Get the full list »

Uncommon Investments (1)

Uncommon’s most recent deal was a Early Stage VC with SecurityPal for . The deal was made on 21-Sep-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
SecurityPal 21-Sep-2022 Early Stage VC Business/Productivity Software
To view Uncommon’s complete investments history, request access »

Ready to get started?

Request a free trial

Uncommon FAQs

  • When was Uncommon founded?

    Uncommon was founded in 2017.

  • Where is Uncommon headquartered?

    Uncommon is headquartered in Cambridge, United Kingdom.

  • What is the size of Uncommon?

    Uncommon has 11 total employees.

  • What industry is Uncommon in?

    Uncommon’s primary industry is Biotechnology.

  • Is Uncommon a private or public company?

    Uncommon is a Private company.

  • What is the current valuation of Uncommon?

    The current valuation of Uncommon is .

  • What is Uncommon’s current revenue?

    The current revenue for Uncommon is .

  • How much funding has Uncommon raised over time?

    Uncommon has raised $49.2M.

  • Who are Uncommon’s investors?

    Global Brain, Heartfelt (Private Equity), Angel Academe, Balderton Capital, and BioIndustry Association are 5 of 21 investors who have invested in Uncommon.

  • Who are Uncommon’s competitors?

    ProFuse Technology, Mosa Meat, and Aleph Farms are competitors of Uncommon.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process